DeepMed Research

ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

Phase 3

Completed

Conditions: Human Immunodeficiency Virus Infection

Interventions: Drug: lopinavir/ritonavir (LPV/r)
Drug: raltegravir (RAL)
Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)

First Posted Date: 2008-07-08

Last Posted Date: 2012-02-14

Lead Sponsor: Abbott

Target Recruit Count: 206

Registration Number: NCT00711009

Locations: 🇺🇸
Site Reference ID/Investigator# 8433, Houston, Texas, United States
🇺🇸
Site Reference ID/Investigator# 8395, Atlanta, Georgia, United States
🇨🇦
Site Reference ID/Investigator# 7831, Toronto, Ontario, Canada

and more 34 locations

Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)

Phase 2

Completed

Conditions: Secondary Hyperparathyroidism
Hemodialysis

Interventions: Drug: Paricalcitol

First Posted Date: 2008-06-19

Last Posted Date: 2011-04-19

Lead Sponsor: Abbott

Target Recruit Count: 107

Registration Number: NCT00701805

Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

Phase 3

Completed

Conditions: Juvenile Rheumatoid Arthritis

Interventions: Biological: Adalimumab

First Posted Date: 2008-06-04

Last Posted Date: 2012-09-10

Lead Sponsor: Abbott

Target Recruit Count: 25

Registration Number: NCT00690573

Locations: 🇯🇵
Site Reference ID/Investigator# 47248, Aichi, Japan
🇯🇵
Site Reference ID/Investigator# 47243, Tokyo, Japan
🇯🇵
Site Reference ID/Investigator# 47244, Tokyo, Japan

and more 9 locations

A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: ABT-335
Drug: Atorvastatin
Drug: Ezetimibe

First Posted Date: 2008-05-21

Last Posted Date: 2010-10-19

Lead Sponsor: Abbott

Target Recruit Count: 18

Registration Number: NCT00681525

Locations: 🇺🇸
Site Reference ID/Investigator# 8087, Gainesville, Florida, United States

Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives

Phase 3

Completed

Conditions: Obesity
Hypertension

Interventions: Drug: sibutramine
Drug: verapamil/trandolapril
Drug: metoprolol/HCT
Drug: felodipine/ramipril

First Posted Date: 2008-05-19

Last Posted Date: 2008-05-19

Lead Sponsor: Abbott

Target Recruit Count: 171

Registration Number: NCT00679653

Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population

Phase 3

Completed

Conditions: Obesity

Interventions: Drug: Sibutramine
Drug: Placebo

First Posted Date: 2008-05-14

Last Posted Date: 2008-05-14

Lead Sponsor: Abbott

Target Recruit Count: 103

Registration Number: NCT00677391

A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis

Phase 3

Completed

Conditions: Ankylosing Spondylitis

Interventions: Biological: adalimumab

First Posted Date: 2008-04-28

Last Posted Date: 2012-01-26

Lead Sponsor: Abbott

Target Recruit Count: 41

Registration Number: NCT00667355

Locations: 🇯🇵
Site Reference # / Investigator 46782, Hokkaido, Japan
🇯🇵
Site Reference # / Investigator 46791, Aichi, Japan
🇯🇵
Site Reference # / Investigator 46798, Fukuoka, Japan

and more 16 locations

Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis

Phase 2

Completed

Conditions: Chronic Kidney Disease on Hemodialysis
Secondary Hyperparathyroidism

Interventions: Drug: Paricalcitol
Drug: Maxacalcitol

First Posted Date: 2008-04-28

Last Posted Date: 2012-01-20

Lead Sponsor: Abbott

Target Recruit Count: 153

Registration Number: NCT00667576

A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab

First Posted Date: 2008-04-25

Last Posted Date: 2012-04-27

Lead Sponsor: Abbott

Target Recruit Count: 7

Registration Number: NCT00666692

Locations: 🇺🇸
Site Reference ID/Investigator# 70333, Hershey, Pennsylvania, United States
🇺🇸
Site Reference ID/Investigator# 70355, Greenville, South Carolina, United States
🇺🇸
Site Reference ID/Investigator# 70354, Bethesda, Maryland, United States

and more 1 locations

Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects

Phase 4

Terminated

Conditions: Secondary Hyperparathyroidism
Dialysis

Interventions: Drug: Calcitriol
Drug: Paricalcitol

First Posted Date: 2008-04-23

Last Posted Date: 2012-01-20

Lead Sponsor: Abbott

Target Recruit Count: 13

Registration Number: NCT00664430

Locations: 🇧🇷
Site Reference ID/Investigator# 7118, Sao Paulo, Brazil
🇧🇷
Site Reference ID/Investigator# 7114, Sao Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy